<DOC>
	<DOC>NCT02183675</DOC>
	<brief_summary>To assess drug drug interaction through pharmacokinetics investigation at steady state of Telmisartan, Amlodipine, and Hydrochlorothiazide (HCTZ) given as three different formulations in healthy Japanese male subjects</brief_summary>
	<brief_title>Pharmacokinetics of Different Formulations of Telmisartan, Amlodipine, and Hydrochlorothiazide (HCTZ) in Japanese Healthy Male Volunteers</brief_title>
	<detailed_description />
	<mesh_term>Telmisartan</mesh_term>
	<mesh_term>Hydrochlorothiazide</mesh_term>
	<mesh_term>Amlodipine</mesh_term>
	<criteria>Inclusion criteria: Healthy Japanese male subjects age &gt;=20 and &lt;=35 years; body weight: &gt;=50 kg and &lt;=80 kg; body mass index: &gt;=18.0 and &lt;=25.0 kg/m2 Without any clinically significant findings and complications on the basis of a complete medical history, including the physical examination, vital signs (blood pressure (BP), pulse rate (PR), body temperature), 12lead electrocardiograms (ECGs), clinical laboratory tests Signed and dated written informed consent prior to admission to the trial in accordance with the Good Clinical Practice (GCP) and the local legislation. Exclusion criteria: Any finding of the medical examination (including BP, PR and ECGs) deviating from normal and of clinical relevance.</criteria>
	<gender>Male</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>35 Years</maximum_age>
	<verification_date>October 2016</verification_date>
</DOC>